Genmab A/S
Close on Nov 19, 2026
Genmab A/S Total Royalty Revenue Earned by Genmab
Total Royalty Revenue Earned by Genmab ($M)
Genmab A/S Total Royalty Revenue Earned by Genmab: $991M in Q3 2026, up 17.8% from a year earlier. That is the highest of the 11 quarters on record here.
Where the Q3 2026 figure comes from
“|| Royalties | $ | 991 | $ | 841 | $ | 2,699 | $ | 2,219”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
Tiered contractual royalties earned on global net sales of partnered antibody medicines commercialized by J&J, Novartis, Amgen, AbbVie, and Roche.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up total Royalty Revenue Earned by Genmab
Cite this data
StockData. (2026). Genmab A/S Total Royalty Revenue Earned by Genmab ($M), quarterly Q1 2024–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/royalties-total
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?